A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019Phase 3Recruiting
- Lead sponsor
- AbbVie (Industry)
- Enrollment
- 170 (estimated)
- Start date
- 5 Aug 2024
- Primary completion
- Mar 2028 (estimated)
- Study completion
- 1 Mar 2028
- Last update posted
- 9 Apr 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 4
Interventions
- Venetoclax Drug
- Acalabrutinib Drug
- Obinutuzumab Drug
Conditions and primary outcome
- Chronic Lymphocytic Leukemia
Primary outcome
Part 1: Percentage of Participants with Treatment-Emergent Laboratory Tumor Lysis Syndrome (TLS)-Venetoclax (Up to 28 Months); Part 1: Percentage of Participants with Hyperkalemia-Venetoclax (Up to 28 Months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06428019.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06428019 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.